三葉草生物-B(02197.HK):獲納入恆生綜合指數
格隆匯2月24日丨三葉草生物-B(02197.HK)宣佈,公司股份獲納入恆生綜合指數成份股,將自2022年3月7日起生效。
恆生綜合指數提供了一個全面的香港市場基準,涵蓋香港聯合交易所有限公司主板上市公司總市值的約95%。獲納入恆生綜合指數令公司股票有資格通過港股通(一個供中國內地和香港投資者之間進行股票交易的渠道)進行交易。
董事會認為,公司股份獲納入恆生綜合指數代表資本市場對公司的表現及價值的認可,這將潛在地幫助提高公司股份的交易流動性,擴大公司的股東基礎並提高全球知名度,這對於公司正在完成其新冠候選疫苗的全球註冊申請以及擴展創新型疫苗和腫瘤療法產品組合是非常重要的一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.